Zoetis Inc.
ZTSNYSE · SIC 2834
$76.03
↓ -0.5%Jul 17 close · end-of-day
Price
1Y↓ -48.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$32.1B
Enterprise Value
$39.2B
P/E
12.5
P/S
3.4
P/B
9.9
EV/EBITDA
—
PEG
1.2
FCF Yield
7.0%
Dividend Yield
2.7%
Revenue (TTM)
$9.5B
Net Income (TTM)
$2.7B
Free Cash Flow (TTM)
$2.2B
Gross Margin
—
Operating Margin
—
Net Margin
28.0%
ROE
82.7%
ROIC
—
Debt / Equity
2.8
Net Cash
-$7.1B
Return 1Y
-48.2%
Company profile
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts.
- CEO
- Kristin C. Peck
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 13,800
- Headquarters
- New Jersey
- Website
- zoetis.com
Management & directors
- Esch KevinExecutive Vice President
- Sarbaugh KeithExecutive Vice President
- Ashton NicholasExecutive Vice President
- Brannan JamieExecutive Vice President
- Driscoll RimmaExecutive Vice President
- Fuller JulieExecutive Vice President
- Ferran Astorga JeannetteExecutive Vice President
- Joseph WettenyChief Financial Officer
- Lagano RoxanneExecutive Vice President
- Peck Kristin CChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-08-06
ZTS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.3B↑ +2.9%
Diluted EPS$1.42↑ +6.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.7B | $7.8B | $8.1B | $8.5B | $9.3B | $9.5B |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | $1.6B | $2.0B | $2.1B | $2.3B | $2.5B | $2.7B |
| Diluted EPS | $3.42 | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 |
| Operating cash flow | $2.1B | $2.2B | $1.9B | $2.4B | $3.0B | $2.9B |
| Free cash flow | $1.7B | $1.7B | $1.3B | $1.6B | $2.3B | $2.3B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | 24.5% | 26.2% | 26.2% | 27.4% | 26.9% | 28.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4B | $2.4B | $2.3B | $2.2B | $2.5B | $2.4B | $2.4B | $2.3B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $624.0M | $682.0M | $581.0M | $602.0M | $718.0M | $721.0M | $632.0M | $601.0M |
| Diluted EPS | $1.37 | $1.50 | $1.29 | $1.34 | $1.61 | $1.63 | $1.44 | $1.42 |
| Operating cash flow | $502.0M | $951.0M | $905.0M | $515.0M | $558.0M | $938.0M | $893.0M | $401.0M |
| Free cash flow | $370.0M | $784.0M | $689.0M | $337.0M | $409.0M | $805.0M | $732.0M | $291.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | 26.4% | 28.6% | 25.1% | 27.4% | 29.2% | 30.0% | 26.2% | 26.6% |
Company news
Jul 15, 2026
Jul 14, 2026
Jul 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-10 | MCCALLISTER MICHAEL B | Gift | 1,209 | $0.00 | $0.00 | filing |
| 2026-05-21 | Stetter Mark | Option exercise | 1,572 | — | — | filing |
| 2026-05-20 | PARENT LOUISE M | Option exercise | 1,944 | — | — | filing |
| 2026-05-20 | PARENT LOUISE M | Option exercise | 10,186 | — | — | filing |
| 2026-05-13 | DAMELIO FRANK A | Buy | 6,650 | $75.39 | $501,343.50 | filing |
| 2026-05-13 | BISARO PAUL | Buy | 2,000 | $75.88 | $151,750.00 | filing |
| 2026-05-11 | MCCALLISTER MICHAEL B | Buy | 3,000 | $77.76 | $233,273.40 | filing |
| 2026-04-30 | Esch Kevin· Executive Vice President | Tax withholding | 75 | $114.97 | $8,622.75 | filing |
| 2026-04-30 | Esch Kevin· Executive Vice President | Option exercise | 259 | — | — | filing |
| 2026-03-31 | Sarbaugh Keith· Executive Vice President | Tax withholding | 524 | $118.21 | $61,942.04 | filing |
| 2026-03-31 | Sarbaugh Keith· Executive Vice President | Option exercise | 1,528 | — | — | filing |
| 2026-03-09 | Norden Gregory | Gift | 1,213 | $0.00 | $0.00 | filing |
| 2026-02-19 | PECK KRISTIN C· Chief Executive Officer | Tax withholding | 3,623 | $127.28 | $461,135.44 | filing |
| 2026-02-19 | Joseph Wetteny· Chief Financial Officer | Tax withholding | 703 | $127.28 | $89,477.84 | filing |
| 2026-02-19 | PARENT LOUISE M | J | 615 | $127.28 | $78,277.20 | filing |
| 2026-02-19 | Brannan Jamie· Executive Vice President | Tax withholding | 566 | $127.28 | $72,040.48 | filing |
| 2026-02-19 | Broadhurst Vanessa | J | 517 | $127.28 | $65,803.76 | filing |
| 2026-02-19 | Hattersley Gavin | J | 481 | $127.28 | $61,221.68 | filing |
| 2026-02-19 | MCCALLISTER MICHAEL B | J | 413 | $127.28 | $52,566.64 | filing |
| 2026-02-19 | Norden Gregory | J | 406 | $127.28 | $51,675.68 | filing |
| 2026-02-19 | Leatherberry Antoinette Renee | J | 406 | $127.28 | $51,675.68 | filing |
| 2026-02-19 | Ashton Nicholas· Executive Vice President | Tax withholding | 392 | $127.28 | $49,893.76 | filing |
| 2026-02-19 | FULLER JULIE· Executive Vice President | Tax withholding | 290 | $127.28 | $36,911.20 | filing |
| 2026-02-19 | Lagano Roxanne· Executive Vice President | Tax withholding | 258 | $127.28 | $32,838.24 | filing |
| 2026-02-19 | Ferran Astorga Jeannette· Executive Vice President | Tax withholding | 190 | $127.28 | $24,183.20 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.